Methods of diagnosing non-alcoholic steatohepatitis (NASH)
View Patent ↗Non-invasive methods for detecting non-alcoholic fatty liver disease (NAFLD) and identifying the presence or absence of non-alcoholic steatohepatitis (NASH) in a subject utilize one or more biomarkers. The methods can differentiate between subjects with NASH and those with simple steatosis. Kits containing one or more agents for measuring the level of the biomarkers can be utilized to perform the described methods.
1. A method for detecting non-alcoholic fatty liver disease (NAFLD) in a subject, the method comprising:
measuring the level of one or more biomarkers in a sample derived from the subject, wherein the one or more biomarkers comprises an adipocytokine, an apoptosis marker, a cell death marker, or any combination thereof; and
analyzing the level in conjunction with a respective reference value range for said one or more biomarkers.
2. The method of claim 1 , wherein analyzing the level in conjunction with a respective reference value range comprises performing linear regression analysis with stepwise variable selection.
3. The method of claim 1 , wherein the NAFLD is simple steatosis, steatosis with non-specific inflammation, non-alcoholic steatohepatitis (NASH), or NASH-related cirrhosis.
4. The method of claim 1 , wherein the one or more biomarkers comprises at least two biomarkers and two or more of the biomarkers are measured.
5. The method of claim 1 , wherein the one or more biomarkers comprises cytokeratin CK-18 (M65 antigen), caspase-cleaved CK-18 (M30-antigen), resistin, adiponectin, visfatin, glucose, insulin, tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), or interleukin 8 (IL-8), or any combination thereof.
6. The method of claim 1 , wherein the one or more biomarkers is cytokeratin CK-18 (M65 antigen), caspase-cleaved CK-18 (M30-antigen), resistin, or adiponectin, or any combination thereof.
7. The method of claim 1 , wherein the one or more biomarkers is cytokeratin CK-18 (M65 antigen), TNF-α, resistin, or adiponectin, or any combination thereof.
8. The method of claim 1 , further comprising measuring a level of necrosis by subtracting the level of apoptosis marker from the level of cell death marker.
9. The method of claim 1 , wherein the subject is a human being.
10. The method of claim 1 , wherein said measuring comprises reacting with a specific antibody against the one or more biomarkers, or any fragment thereof containing an antigenic determinant.
11. The method of claim 10 , wherein the specific antibody comprises a whole immunoglobulin molecule, a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a recombinant fragment of antibody, an Fab fragment, an Fab′ fragment, an F(ab′)2 fragment, an Fv fragment, or an scFv fragment, or any combination thereof.
12. The method of claim 1 , wherein said measuring the level of one or more biomarkers comprises conducting enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunofluorescent assay (IFA), sandwich assay, magnetic capture, microsphere capture, Western Blot, surface enhanced Raman spectroscopy (SERS), flow cytometry, or mass spectrometry.
13. The method of claim 1 , wherein the sample comprises blood, serum, plasma, urine, saliva, cerebrospinal fluid, tissue, or tissue extract.
14. The method of claim 1 , wherein said measuring comprises an adipocytokine, and apoptosis marker, a cell death marker, or any combination thereof, in a multiplex assay.
15. The method of claim 1 , the method further comprising:
generating data on the sample indicating the level of the one or more biomarkers;
transforming the data into computer readable form;
operating a computer to execute an algorithm, wherein the algorithm determines the level of said one or more biomarkers; and
displaying the level.
16. A method for screening a subject to identify the presence or absence of non-alcoholic steatohepatitis (NASH) in the subject, the method comprising:
measuring the level of a plurality of biomarkers in a sample derived from the subject, wherein the plurality of biomarkers comprises an adipocytokine, an apoptosis marker, and a cell death marker; and
analyzing the levels in conjunction with respective reference value ranges for said plurality of biomarkers.
17. The method of claim 16 , wherein analyzing the levels in conjunction with respective reference value ranges comprises performing linear regression analysis.
18. The method of claim 16 , further comprising utilizing Homeostasis Model Assessment (HOMA) to identify the presence or absence of NASH.
19. The method of claim 16 , wherein the reference value ranges of each of the plurality of biomarkers represent a subject without NASH.
20. A method for evaluating the effect of an agent for treating non-alcoholic steatohepatitis (NASH) in a subject, the method comprising:
analyzing the level of each of one or more biomarkers in samples derived from the subject before and after the subject is treated with said agent, in conjunction with respective reference value ranges for said one or more biomarkers, wherein the one or more biomarkers comprises an adipocytokine, an apoptosis marker, a cell death marker, or any combination thereof.
21. A method for monitoring the efficacy of a therapy for treating non-alcoholic steatohepatitis (NASH) in a subject, the method comprising:
analyzing the level of each of one or more biomarkers in samples derived from the subject before and after the subject undergoes said therapy, in conjunction with respective reference value ranges for said one or more biomarkers, wherein the one or more biomarkers comprises an adipocytokine, an apoptosis marker, a cell death marker, or any combination thereof.
22. A kit comprising a package, the package containing at least four agents, for measuring the level of at least four analytes of interest, wherein the at least four analytes of interest comprise cytokeratin CK-18 (M65 antigen), caspase-cleaved CK-18 (M30-antigen), resistin, and adiponectin.
23. The kit of claim 22 , wherein the at least four agents comprise at least one of an antibody of cytokeratin CK-18 (M65 antigen), an antibody of caspase-cleaved CK-18 (M30-antigen), an antibody of resistin, an antibody of adiponectin, and a combination thereof.
24. The kit of claim 22 , further comprising at least four separate containers inside the package, wherein each separate container contains a respective one of the at least four agents.
25. The kit of claim 22 , further comprising one or more control reference sample.
26. The kit of claim 22 , wherein the package comprises a box, a wrapper enveloping the box, and instructions for using the kit.
27. The kit of claim 22 , further comprising information, in electronic or paper form, comprising reference levels for comparing to detected levels of each of the at least four analytes of interest.
28. The kit of claim 22 , further comprising information, in electronic or paper form, comprising instructions to correlate the detected levels of each of the at least four analytes of interest with non-alcoholic fatty liver disease (NAFLD).